Subgroup Results from KARDIA-2 Study on Zilebesiran

This document is a report detailing the subgroup results from the KARDIA-2 study, which investigates the impact of demographic and baseline disease characteristics on the response to zilebesiran in patients with hypertension that is uncontrolled by standard oral antihypertensive medications. The study design includes a 6-month double-blind period and an open-label run-in phase, focusing on patients aged 18 to 75 years with untreated or treated hypertension. The primary endpoint is the change from baseline in 24-hour mean ambulatory systolic blood pressure (SBP) at Month 3, with key secondary endpoints including changes in office SBP. The report presents data on the efficacy and safety of zilebesiran, highlighting that treatment resulted in significant reductions in SBP compared to placebo across various subgroups. It also notes the safety profile of zilebesiran, indicating that most adverse events were mild and transient. Overall, the findings suggest that zilebesiran may be a promising treatment for patients with uncontrolled hypertension.